The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD)
© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Clinical and molecular subcategories of inflammatory bowel disease (IBD) are needed to discover mechanisms of disease and predictors of response and disease relapse. We aimed to develop a study of a prospective adult research cohort with IBD (SPARC IBD) including longitudinal clinical and patient-reported data and biosamples.
METHODS: We established a cohort of adults with IBD from a geographically diverse sample of patients across the United States with standardized data and biosample collection methods and sample processing techniques. At enrollment and at time of lower endoscopy, patient-reported outcomes (PRO), clinical data, and endoscopy scoring indices are captured. Patient-reported outcomes are collected quarterly. The quality of clinical data entry after the first year of the study was assessed.
RESULTS: Through January 2020, 3029 patients were enrolled in SPARC, of whom 66.1% have Crohn's disease (CD), 32.2% have ulcerative colitis (UC), and 1.7% have IBD-unclassified. Among patients enrolled, 990 underwent colonoscopy. Remission rates were 63.9% in the CD group and 80.6% in the UC group. In the quality study of the cohort, there was 96% agreement on year of diagnosis and 97% agreement on IBD subtype. There was 91% overall agreement describing UC extent as left-sided vs extensive or pancolitis. The overall agreement for CD behavior was 83%.
CONCLUSION: The SPARC IBD is an ongoing large prospective cohort with longitudinal standardized collection of clinical data, biosamples, and PROs representing a unique resource aimed to drive discovery of clinical and molecular markers that will meet the needs of precision medicine in IBD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Inflammatory bowel diseases - 28(2022), 2 vom: 01. Feb., Seite 192-199 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Raffals, Laura E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biobank |
|---|
| Anmerkungen: |
Date Completed 31.03.2022 Date Revised 21.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ibd/izab071 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329796887 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329796887 | ||
| 003 | DE-627 | ||
| 005 | 20231225205911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ibd/izab071 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM329796887 | ||
| 035 | |a (NLM)34436563 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Raffals, Laura E |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2022 | ||
| 500 | |a Date Revised 21.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Clinical and molecular subcategories of inflammatory bowel disease (IBD) are needed to discover mechanisms of disease and predictors of response and disease relapse. We aimed to develop a study of a prospective adult research cohort with IBD (SPARC IBD) including longitudinal clinical and patient-reported data and biosamples | ||
| 520 | |a METHODS: We established a cohort of adults with IBD from a geographically diverse sample of patients across the United States with standardized data and biosample collection methods and sample processing techniques. At enrollment and at time of lower endoscopy, patient-reported outcomes (PRO), clinical data, and endoscopy scoring indices are captured. Patient-reported outcomes are collected quarterly. The quality of clinical data entry after the first year of the study was assessed | ||
| 520 | |a RESULTS: Through January 2020, 3029 patients were enrolled in SPARC, of whom 66.1% have Crohn's disease (CD), 32.2% have ulcerative colitis (UC), and 1.7% have IBD-unclassified. Among patients enrolled, 990 underwent colonoscopy. Remission rates were 63.9% in the CD group and 80.6% in the UC group. In the quality study of the cohort, there was 96% agreement on year of diagnosis and 97% agreement on IBD subtype. There was 91% overall agreement describing UC extent as left-sided vs extensive or pancolitis. The overall agreement for CD behavior was 83% | ||
| 520 | |a CONCLUSION: The SPARC IBD is an ongoing large prospective cohort with longitudinal standardized collection of clinical data, biosamples, and PROs representing a unique resource aimed to drive discovery of clinical and molecular markers that will meet the needs of precision medicine in IBD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a biobank | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a precision medicine | |
| 650 | 4 | |a ulcerative colitis | |
| 650 | 7 | |a Osteonectin |2 NLM | |
| 700 | 1 | |a Saha, Sumona |e verfasserin |4 aut | |
| 700 | 1 | |a Bewtra, Meenakshi |e verfasserin |4 aut | |
| 700 | 1 | |a Norris, Cecile |e verfasserin |4 aut | |
| 700 | 1 | |a Dobes, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Heller, Caren |e verfasserin |4 aut | |
| 700 | 1 | |a O'Charoen, Sirimon |e verfasserin |4 aut | |
| 700 | 1 | |a Fehlmann, Tara |e verfasserin |4 aut | |
| 700 | 1 | |a Sweeney, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Weaver, Alandra |e verfasserin |4 aut | |
| 700 | 1 | |a Bishu, Shrinivas |e verfasserin |4 aut | |
| 700 | 1 | |a Cross, Raymond |e verfasserin |4 aut | |
| 700 | 1 | |a Dassopoulos, Themistocles |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Yarur, Andres |e verfasserin |4 aut | |
| 700 | 1 | |a Hudesman, David |e verfasserin |4 aut | |
| 700 | 1 | |a Parakkal, Deepak |e verfasserin |4 aut | |
| 700 | 1 | |a Duerr, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Caldera, Freddy |e verfasserin |4 aut | |
| 700 | 1 | |a Korzenik, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Pekow, Joel |e verfasserin |4 aut | |
| 700 | 1 | |a Wells, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Bohm, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Perera, Lilani |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Manreet |e verfasserin |4 aut | |
| 700 | 1 | |a Ciorba, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Snapper, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Scoville, Elizabeth A |e verfasserin |4 aut | |
| 700 | 1 | |a Dalal, Sushila |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Uni |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, James D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammatory bowel diseases |d 1995 |g 28(2022), 2 vom: 01. Feb., Seite 192-199 |w (DE-627)NLM094498598 |x 1536-4844 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:2 |g day:01 |g month:02 |g pages:192-199 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ibd/izab071 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 2 |b 01 |c 02 |h 192-199 | ||